Icotinib vs Lazertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Icotinib

Marketed by Betta Pharmaceuticals Co.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01040780 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.

Next expected readout: October 2030 · NCT07458919 (registry estimate)

Reported efficacy

Progression Free Survival (12 months): Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006 (met)

Result source: NCT01719536

Lazertinib

Marketed by Johnson & Johnson and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04248829 · Phase 3 · completed

The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).

Next expected readout: December 2026 · NCT05463224 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)

Result source: NCT04487080

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIcotinibLazertinib
PFS, median4.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results
OS, median13.3 vs 13.9vs Gefitinibn 199NCT010407809.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396
ORR—Not posted · NCT0420607276% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396
Duration of response, median—Not posted · NCT0420607219.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396

PFS, median

Icotinib
4.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result
Lazertinib
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results

OS, median

Icotinib
13.3 vs 13.9vs Gefitinibn 199NCT01040780
Lazertinib
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396

ORR

Icotinib
—Not posted · NCT04206072
Lazertinib
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396

Duration of response, median

Icotinib
—Not posted · NCT04206072
Lazertinib
19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Icotinib: 3 of 4 rows · Lazertinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcotinibLazertinib
Dropout rate
0.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
0%
NCT02264210 · Phase 2 · registry result, not featured evidence
44.9%240 mgb
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
78.1%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
75%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.5%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
80.2%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—
NCT02264210 · Phase 2 · registry result, not featured evidence
9.7%240 mgb
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
—Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
—320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Serious AEs
6.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.3%
NCT02264210 · Phase 2 · registry result, not featured evidence
26%240 mgb
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
48.7%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
35.2%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
52.1%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
32.3%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
66.7%240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
46.2%320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
rash 40.5%
diarrhea 21.5%
pain 18%
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
rash 39.7% (placebo 0%)
diarrhoea 20.6% (placebo 0%)
pain 11.1% (placebo 0%)
NCT02264210 · Phase 2 · registry result, not featured evidence
240 mgb
paraesthesia 39.3%
rash 36.2%
pruritus 26.5%
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
paronychia 68.4%
infusion related reaction 62%
rash 61.8%
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
rash 44.6%
diarrhoea 31.9%
paronychia 28.6%
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
neutropenia 65.8%
thrombocytopenia 59.3%
infusion related reaction 54%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
infusion related reaction 56.9%
neutropenia 56.2%
nausea 44.6%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
240 mg
anaemia 46.7%
diarrhoea 46.7%
aspartate aminotransferase increased 26.7%
NCT04075396 · Phase 1/2 · registry result, not featured evidence
320 mg
nausea 61.5%
diarrhoea 53.8%
arthralgia 23.1%
NCT04075396 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Icotinib

Overall Survival 13.3 vs 13.9 Gefitinib months
time to event · months
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Stable Disease 47.7% (n=199) vs 47.7% (n=196) Gefitinib
absolute value · percentage points
Stable Disease (SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Progressive Disease 21.1% (n=199) vs 20.5% (n=196) Gefitinib
absolute value · percentage points
Progressive Disease (PD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control 75.4% (n=199) vs 74.9% (n=196) Gefitinib
absolute value · percentage points
Disease Control (CR+PR+SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease-Free Survival 96.1 vs 84 placebo % of time @ 156wk
absolute value · % of time
NCT02264210 · Phase 2 · registry result, not featured evidence

Lazertinib

ORR 76% (n=196) vs 76.1% (n=197) Gefitnib240 mg
responder rate · % of participants
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 19.4 vs 8.3 Gefitnib months240 mg
time to event · months
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 93.9% (n=196) vs 93.9% (n=197) Gefitnib240 mg
responder rate · % of participants
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival 25% (n=196) vs 32.5% (n=197) Gefitnib240 mg
event count · % of participants
Death
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 · converted to % from 49 Participants as posted
ORR 26.7% (n=15)240 mg
responder rate · % of participants
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
7.7% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Duration of Response NA months240 mg
time to event · months
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
2.8 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Disease Control 60% (n=15)240 mg
responder rate · % of participants
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
53.8% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Tumor Size -5.37% (n=14)240 mg
percent change · % of baseline
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
9.56% (n=12)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
PFS 3.1 months240 mg
time to event · months
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
4.2 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Overall Survival 9.1 months240 mg
time to event · months
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
7.7 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · Lazertinib's landscape